Tagrix (Osimertinib Mesylate) is prescribed to treat metastatic non-small cell lung cancer in patients with T790M mutation in the epidermal growth factor receptor (EGFR) gene, who developed progressive disease during and after EGFR tyrosine kinase inhibitor therapy. The medication can be prescribed only after the mutation has been confirmed by the laboratory tests.
